PaxMedica, Inc. Common Stock
PXMD
PXMD was delisted on the 1st of May, 2024.
10 hedge funds and large institutions have $308K invested in PaxMedica, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
75% more capital invested
Capital invested by funds: $176K → $308K (+$132K)
25% more funds holding
Funds holding: 8 → 10 (+2)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$130K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$72.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$32.3K |
| 4 |
VF
Virtu Financial
New York
|
+$6.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$37K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$24.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.41K |
| 4 |
Barclays
London,
United Kingdom
|
-$204 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $105K | +$130K | +3,233 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $58.8K | +$72.7K | +1,811 | New |
|
3
State Street
Boston,
Massachusetts
| $41.8K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $33.9K | -$37K | -922 | -47% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $26.1K | +$32.3K | +805 | New |
|
|
VF
6
Virtu Financial
New York
| $24K | +$6.42K | +160 | +27% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $8.04K | -$24.4K | -608 | -71% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $8K | -$3.41K | -85 | -26% |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $1.91K | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $44 | – | – | – |
|
|
11
Barclays
London,
United Kingdom
| – | -$204 | -6 | Closed |
|
PXMD Hedge Fund Activity: Q1 2023 in Review
10 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PaxMedica, Inc. Common Stock (PXMD) for Q1 2023, worth a combined $308K — up 75% from $176K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PXMD positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $130K. The largest seller was UBS Group, cutting an estimated $37K.
- 10 institutional investors held PaxMedica, Inc. Common Stock (PXMD) as of Q1 2023, up from 8 in Q4 2022.
- Funds reported $308K of PaxMedica, Inc. Common Stock stock for Q1 2023, up 75% quarter-over-quarter.
- 3 funds opened new PaxMedica, Inc. Common Stock positions in Q1 2023 and 1 closed out, a net change of +2 holders.
- The largest PaxMedica, Inc. Common Stock buyer in Q1 2023 was Vanguard Group, an estimated $130K added.
- The largest PaxMedica, Inc. Common Stock seller in Q1 2023 was UBS Group, an estimated $37K sold.
Based on aggregated 13F filings for Q1 2023.